tetano
Editor, Senior Moderator
Pathogens
. 2021 Aug 19;10(8):1051.
doi: 10.3390/pathogens10081051.
Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections
Balamurugan Shanmugaraj[SUP] 1 [/SUP], Konlavat Siriwattananon[SUP] 2 3 [/SUP], Ashwini Malla[SUP] 1 [/SUP], Waranyoo Phoolcharoen[SUP] 1 2 [/SUP]
Affiliations
Abstract
The emerging human coronavirus infections in the 21st century remain a major public health crisis causing worldwide impact and challenging the global health care system. The virus is circulating in several zoonotic hosts and continuously evolving, causing occasional outbreaks due to spill-over events occurring between animals and humans. Hence, the development of effective vaccines or therapeutic interventions is the current global priority in order to reduce disease severity, frequent outbreaks, and to prevent future infections. Vaccine development for newly emerging pathogens takes a long time, which hinders rapid immunization programs. The concept of plant-based pharmaceuticals can be readily applied to meet the recombinant protein demand by means of transient expression. Plants are evolved as an expression platform, and they bring a combination of unique interests in terms of rapid scalability, flexibility, and economy for industrial-scale production of effective vaccines, diagnostic reagents, and other biopharmaceuticals. Plants offer safe biologics to fulfill emergency demands, especially during pandemic situations or outbreaks caused by emerging strains. This review highlights the features of a plant expression platform for producing recombinant biopharmaceuticals to combat coronavirus infections with emphasis on COVID-19 vaccine and biologics development.
Keywords: COVID-19; SARS-CoV-2; biopharmaceuticals; coronavirus; molecular farming; plant expression; recombinant proteins.
. 2021 Aug 19;10(8):1051.
doi: 10.3390/pathogens10081051.
Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections
Balamurugan Shanmugaraj[SUP] 1 [/SUP], Konlavat Siriwattananon[SUP] 2 3 [/SUP], Ashwini Malla[SUP] 1 [/SUP], Waranyoo Phoolcharoen[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34451516
- DOI: 10.3390/pathogens10081051
Abstract
The emerging human coronavirus infections in the 21st century remain a major public health crisis causing worldwide impact and challenging the global health care system. The virus is circulating in several zoonotic hosts and continuously evolving, causing occasional outbreaks due to spill-over events occurring between animals and humans. Hence, the development of effective vaccines or therapeutic interventions is the current global priority in order to reduce disease severity, frequent outbreaks, and to prevent future infections. Vaccine development for newly emerging pathogens takes a long time, which hinders rapid immunization programs. The concept of plant-based pharmaceuticals can be readily applied to meet the recombinant protein demand by means of transient expression. Plants are evolved as an expression platform, and they bring a combination of unique interests in terms of rapid scalability, flexibility, and economy for industrial-scale production of effective vaccines, diagnostic reagents, and other biopharmaceuticals. Plants offer safe biologics to fulfill emergency demands, especially during pandemic situations or outbreaks caused by emerging strains. This review highlights the features of a plant expression platform for producing recombinant biopharmaceuticals to combat coronavirus infections with emphasis on COVID-19 vaccine and biologics development.
Keywords: COVID-19; SARS-CoV-2; biopharmaceuticals; coronavirus; molecular farming; plant expression; recombinant proteins.